Zai Lab Competitors

Vertex Pharmaceuticals (NASDAQ:VRTX) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Vertex Pharmaceuticals and Zai Lab's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Zai Lab's top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Vertex Pharmaceuticals and Zai Lab, as provided by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus price target of $293.2083, suggesting a potential upside of 35.76%. Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Vertex Pharmaceuticals' higher probable upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Zai Lab.

Summary

Vertex Pharmaceuticals beats Zai Lab on 12 of the 15 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Takeda Pharmaceutical and Zai Lab's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Takeda Pharmaceutical and Zai Lab's top-line revenue, earnings per share and valuation.

Takeda Pharmaceutical has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Takeda Pharmaceutical and Zai Lab, as provided by MarketBeat.com.

Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Takeda Pharmaceutical.

Summary

Takeda Pharmaceutical beats Zai Lab on 8 of the 13 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Regeneron Pharmaceuticals and Zai Lab's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Zai Lab's top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Zai Lab, as provided by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus price target of $644.1739, suggesting a potential upside of 31.35%. Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Regeneron Pharmaceuticals' higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Zai Lab.

Summary

Regeneron Pharmaceuticals beats Zai Lab on 12 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Risk & Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Alexion Pharmaceuticals and Zai Lab's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Zai Lab's top-line revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Alexion Pharmaceuticals and Zai Lab, as provided by MarketBeat.com.

Alexion Pharmaceuticals presently has a consensus price target of $153.4286, suggesting a potential downside of 8.48%. Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Zai Lab on 11 of the 15 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Zai Lab has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Insider & Institutional Ownership

81.3% of Zai Lab shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Zai Lab and BeiGene's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Zai Lab and BeiGene's gross revenue, earnings per share (EPS) and valuation.

Zai Lab has higher earnings, but lower revenue than BeiGene. Zai Lab is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zai Lab and BeiGene, as provided by MarketBeat.com.

Zai Lab presently has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. BeiGene has a consensus price target of $319.3750, suggesting a potential upside of 2.67%. Given Zai Lab's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zai Lab is more favorable than BeiGene.

Summary

Zai Lab beats BeiGene on 10 of the 14 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Insider & Institutional Ownership

81.3% of Zai Lab shares are owned by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Zai Lab and Royalty Pharma's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Zai Lab and Royalty Pharma's gross revenue, earnings per share (EPS) and valuation.

Royalty Pharma has lower revenue, but higher earnings than Zai Lab.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zai Lab and Royalty Pharma, as provided by MarketBeat.com.

Zai Lab presently has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Royalty Pharma has a consensus price target of $51.8750, suggesting a potential upside of 20.05%. Given Zai Lab's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zai Lab is more favorable than Royalty Pharma.

Summary

Zai Lab beats Royalty Pharma on 5 of the 6 factors compared between the two stocks.